Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841473 | 0.76 | TNKS2 (0.30) | TNKS2 | |
| SCHEMBL21586265 | 0.64 | ALDH1A1 (0.30) | — | |
| SCHEMBL6010814 | 0.61 | GDA (0.32) | — | |
| SCHEMBL15386158 | 0.61 | ALDH1A1 (0.35) | — | |
| SCHEMBL3500581 | 0.60 | ALDH1A1 (0.37) | GSK3B | |
| SCHEMBL30642415 | 0.60 | — | — | |
| SCHEMBL4874802 | 0.60 | CYP1A2 (0.30) | — | |
| Water SCHEMBL11632248 | 0.59 | — | — | |
| SCHEMBL17159951 | 0.56 | ALDH1A1 (0.55) | — | |
| SCHEMBL15758842 | 0.53 | GDA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759347-B2 | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20090124628-A1 | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-1761536-B1 | NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1761536-A1 | NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060004014-A1 | 2-Benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| WO-2005123736-A1 | NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124628-A1 | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments | QDPR, DHPS, CYP51A1 | GSK3B 4150/4885TNKS2 1520/4885 |
| US-20060004014-A1 | 2-Benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments | QDPR, DHPS, CYP51A1 | GSK3B 4150/4885TNKS2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.